Latest news for Vivesto (OTC:OASMY) Stock

Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.

Biotech

News

Health Care

Contracts

General

KZIA

OASMY

Kazia Therapeutics Ltd (NASDAQ: KZIA) has 

Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian Cancer

Vivesto AB

Guidance

DiamondRock Hospitality Raises FY24 Adj. FFO Guidance From $0.91-$1.00 To $0.95-$1.00

WIIM

ARDX

Ardelyx shares are trading higher after the company reported better-than-expected Q2 financial results.

CERS

Cerus shares are trading higher after the company reported better-than-expected Q2 EPS results and raised its FY24 product revenue guidance above estimates.

WLDN

Willdan Group shares are trading higher after the company reported better-than-expected Q2 financial results.

MasTec shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results.

Ero Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERO#NYSE">ERO</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.16 by 12.5 percent. This is a 25 percent decrease over earnings of $0.24 per share from the same period last year. The company reported quarterly sales of $117.100 million which missed the analyst consensus estimate of $120.297 million by 2.66 percent. This is a 11.63 percent increase over sales of $104.900 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Ero Copper Q2 2024 Adj. EPS $0.18 Beats $0.16 Estimate, Sales $117.100M Miss $120.297M Estimate

Saul Centers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFS#NYSE">BFS</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.77 by 7.79 percent. This is a 6.41 percent increase over earnings of $0.78 per share from the same period last year. The company reported quarterly sales of $66.94 million which beat the analyst consensus estimate of $65.54 million by 2.14 percent. This is a 5.08 percent increase over sales of $63.71 million the same period last year.

Saul Centers Q2 FFO $0.83 Beats $0.77 Estimate, Sales $66.94M Beat $65.54M Estimate

WillScot Mobile Mini shares are trading lower after the company reported worse-than-expected Q2 sales results.

Zymeworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) (the "Company"), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that its Board of Directors has authorized a Share Repurchase Program under which the Company may repurchase up to $60.0 million of the Company's outstanding common stock, par value $0.00001 per share. Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024, demonstrating the Company's near-term commitment to returning capital to stockholders. Zymeworks intends to reserve the remaining $30.0 million for future repurchases, ensuring flexibility to adapt to market conditions and growth opportunities.

Buybacks

ZYME

Zymeworks Announces Share Repurchase Program Of Up To $60M Of Common Stock

<ul>
<li>3Q24 Contribution Profit1&nbsp;guidance&nbsp;of&nbsp;$35 million&nbsp;to&nbsp;$45 million</li>
<li>3Q24 Adjusted EBITDA1&nbsp;guidance&nbsp;of&nbsp;$(70)&nbsp;million to&nbsp;$(60)&nbsp;million</li>
</ul>

OPEN

Opendoor Expects Q3 Revenue Of $1.2B - $1.3B, Est $1.59B

Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.76) by 6.58 percent. This is a 22.73 percent decrease over losses of $(0.66) per share from the same period last year. The company reported quarterly sales of $7.33 million which missed the analyst consensus estimate of $8.44 million by 13.13 percent. This is a 30.01 percent decrease over sales of $10.48 million the same period last year.

MRUS

Merus Q2 EPS $(0.81) Misses $(0.76) Estimate, Sales $7.33M Miss $8.44M Estimate

Bausch Health shares are trading lower. The company reported Q2 financial results.

LASR

nLIGHT Sees Q4 Revenues $53M-$58M vs $55.6M Est.

BFLY

Butterfly Network shares are trading higher after the company reported better-than-expected Q2 financial results.

Opendoor Technologies shares are trading lower. The company reported Q2 financial results.

Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) reported quarterly earnings of $0.60 per share which missed the analyst consensus estimate of $0.61 by 1.64 percent. This is a 1.64 percent decrease over earnings of $0.61 per share from the same period last year. The company reported quarterly sales of $1.760 billion which beat the analyst consensus estimate of $1.745 billion by 0.88 percent. This is a 5.11 percent increase over sales of $1.675 billion the same period last year.

Select Medical Hldgs Q2 2024 Adj. EPS $0.60 Misses $0.61 Estimate, Sales $1.760B Beat $1.745B Estimate

Integral Ad Science shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY24 revenue guidance above estimates.

Sprout Social shares are trading lower. The company reported Q2 financial results.

Transaction Represents Initial Residential Investment by RMR
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.rmrgroup.com&amp;esheet=54103155&amp;newsitemid=20240801352089&amp;lan=en-US&amp;anchor=The+RMR+Group+%28Nasdaq%3A+RMR%29&amp;index=1&amp;md5=714b2221a7120d410fe1119f92191563">The RMR Group (NASDAQ:</a><a href="https://www.benzinga.com/stock/RMR#NASDAQ">RMR</a>) today announced that it has acquired The Ridge at Lowry, a 240-unit garden-style apartment community located at 10000 E. Alameda Avenue in Denver, Colorado, for a purchase price of $70.0 million. The property will be rebranded as ARIUM at Lowry under RMR's consumer-focused brand, ARIUM, and will undergo extensive interior and exterior renovations.

The RMR Group Announces Acquisition Of A Denver Multifamily Property For $70M

VREX

Varex Expects Q4 Revenues To Be $190M - $210M (Est $211.15M), Adj EPS To Be $0.00 - $0.15 (Est $0.22); Company Says Outlook Reflects Challenging Market Conditions

Vivesto

Kazia Therapeutics Ltd&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/kzia#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">KZIA</a>) has&nbsp;<a class="editor-rtfLink" href="https://www.prnewswire.co.uk/news-releases/kazia-licenses-cantrixil-a-clinical-stage-first-in-class-ovarian-cancer-drug-candidate-to-oasmia-pharmacetical-ab-885769945.html" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">entered an exclusive worldwide licensing</a>&nbsp;agreement with&nbsp;Oasmia Pharmaceutical AB&nbsp;(OTC:<a class="ticker" href="/stock/OASMY#OTC">OASMY</a>) for Cantrixil under development the treatment of ovarian cancer.

<ul>
	<li>The agreement will see Sweden-based Oasmia assume exclusive worldwide rights to develop and commercialize Cantrixil for all indications, with an initial focus on ovarian cancer.</li>
	<li>Oasmia&#39;s lead product, Apealea (paclitaxel micellar), is approved in Europe for adult patients with the first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer, and is in late-stage development in the U.S.</li>
	<li>Oasmia expects to commence a Phase 2 study of Cantrixil in ovarian cancer in 2022.</li>
	<li>Under the terms of the agreement, Oasmia will make an upfront payment of $4 million to Kazia, with contingent milestone payments of up to $42 million and double-digit royalties on commercial sales.</li>
	<li>Cantrixil is a proprietary formulation of the potent and selective third-generation benzopyran, TRX-E-002-1, that targets the entire spectrum of cancer cells, including chemotherapy-resistant tumor-initiating cells (cancer stem cells) thought to be responsible for disease relapse.</li>
	<li>In December last year, Kazia&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/20/12/n18715681/top-line-final-data-from-cantrixil-phase-i-study-confirms-prior-positive-efficacy-and-safety-signa" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">announced&nbsp;</a>a Phase 1 study&#39;s top-line results and determined the maximum tolerated dose of Cantrixil to be 5 mg/kg.</li>
	<li>Price Action:&nbsp;KZIA closed 3.9% lower at 9.9 on Friday.</li>
</ul>

Oasmia's Rights Issue Has Been Oversubscribed

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Vivesto

News

Latest news for Vivesto (OTC:OASMY) Stock

Monday, March 01, 2021

Friday, December 06, 2019